| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Denise Cristian Ferreira Neto, Josélia Alencar Lima, Joyce Sobreiro Francisco Diz de Almeida, Tanos Celmar Costa França, Claudia Jorge do Nascimento, José Daniel Figueroa Villa. New semicarbazones as gorge-spanning ligands of acetylcholinesterase and potential new drugs against Alzheimer's disease: Synthesis, molecular modeling, NMR, and biological evaluation. Journal of biomolecular structure & dynamics. vol 36. issue 15. 2019-06-20. PMID:29198175. |
new semicarbazones as gorge-spanning ligands of acetylcholinesterase and potential new drugs against alzheimer's disease: synthesis, molecular modeling, nmr, and biological evaluation. |
2019-06-20 |
2023-08-13 |
Not clear |
| Catarina Oliveira, Donatella Bagetta, Fernando Cagide, José Teixeira, Ricardo Amorim, Tiago Silva, Jorge Garrido, Fernando Remião, Eugenio Uriarte, Paulo J Oliveira, Stefano Alcaro, Francesco Ortuso, Fernanda Borge. Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents. European journal of medicinal chemistry. vol 174. 2019-06-17. PMID:31029943. |
the discovery of new chemical entities endowed with potent and selective acetylcholinesterase (ache) and/or butyrylcholinesterase (bche) inhibitory activity is still a relevant subject for alzheimer's disease therapy. |
2019-06-17 |
2023-08-13 |
human |
| Jing Zhao, Michael J Hylin, Nobuhide Kobori, Kimberly N Hood, Anthony N Moore, Pramod K Das. Post-Injury Administration of Galantamine Reduces Traumatic Brain Injury Pathology and Improves Outcome. Journal of neurotrauma. vol 35. issue 2. 2019-06-14. PMID:29088998. |
galantamine (u.s. food and drug administration approved for the treatment of vascular dementia and alzheimer's disease) has been shown to inhibit acetylcholinesterase activity and allosterically potentiate nicotinic receptor signaling. |
2019-06-14 |
2023-08-13 |
Not clear |
| Lupe C Espinoza, Marisol Vacacela, Beatriz Clares, Maria Luisa Garcia, Maria-Jose Fabrega, Ana C Calpen. Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer's Disease: in vitro and ex vivo Characterization. CNS & neurological disorders drug targets. vol 17. issue 1. 2019-05-31. PMID:29299992. |
donepezil (dpz) is widely prescribed as a specific and reversible acetylcholinesterase inhibitor for the symptomatic treatment of mild to moderate alzheimer's disease (ad). |
2019-05-31 |
2023-08-13 |
Not clear |
| Kanzal Iman, Muhammad Usman Mirza, Nauman Mazhar, Michiel Vanmeert, Imran Irshad, Mohammad A Kama. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease. CNS & neurological disorders drug targets. vol 17. issue 1. 2019-05-31. PMID:29336270. |
in silico structure-based identification of novel acetylcholinesterase inhibitors against alzheimer's disease. |
2019-05-31 |
2023-08-13 |
Not clear |
| Fatemeh Ahmadi-Motamayel, Mohammad Taghi Goodarzi, Shabnam Tarazi, Mehrangiz Vahabia. Evaluation of salivary acetylcholinesterase and pseudocholinesterase in patients with Alzheimer's disease: A case-control study. Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry. vol 39. issue 1. 2019-05-31. PMID:30536408. |
evaluation of salivary acetylcholinesterase and pseudocholinesterase in patients with alzheimer's disease: a case-control study. |
2019-05-31 |
2023-08-13 |
human |
| Fatemeh Ahmadi-Motamayel, Mohammad Taghi Goodarzi, Shabnam Tarazi, Mehrangiz Vahabia. Evaluation of salivary acetylcholinesterase and pseudocholinesterase in patients with Alzheimer's disease: A case-control study. Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry. vol 39. issue 1. 2019-05-31. PMID:30536408. |
the aim of this study was to evaluate acetylcholinesterase (ache) and pseudocholinesterase (pche) in whole saliva in patients with alzheimer's disease (ad) and in healthy subjects. |
2019-05-31 |
2023-08-13 |
human |
| Shigeki Hirano, Hitoshi Shinotoh, Hitoshi Shimada, Tsuneyoshi Ota, Koichi Sato, Noriko Tanaka, Ming-Rong Zhang, Makoto Higuchi, Kiyoshi Fukushi, Toshiaki Irie, Satoshi Kuwabara, Tetsuya Suhar. Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's disease : JAD. vol 62. issue 4. 2019-05-28. PMID:29562505. |
voxel-based acetylcholinesterase pet study in early and late onset alzheimer's disease. |
2019-05-28 |
2023-08-13 |
Not clear |
| Marta Goschorska, Izabela Gutowska, Irena Baranowska-Bosiacka, Katarzyna Piotrowska, Emilia Metryka, Krzysztof Safranow, Dariusz Chlube. Influence of Acetylcholinesterase Inhibitors Used in Alzheimer's Disease Treatment on the Activity of Antioxidant Enzymes and the Concentration of Glutathione in International journal of environmental research and public health. vol 16. issue 1. 2019-05-28. PMID:30577562. |
influence of acetylcholinesterase inhibitors used in alzheimer's disease treatment on the activity of antioxidant enzymes and the concentration of glutathione in it has been reported that donepezil and rivastigmine, the acetylcholinesterase (ache) inhibitors commonly used in the treatment of alzheimer's disease (ad), do not only inhibit ache but also have antioxidant properties. |
2019-05-28 |
2023-08-13 |
cat |
| Kazuki Terada, Keisuke Migita, Yukari Matsushima, Yumi Sugimoto, Chiaki Kamei, Taichi Matsumoto, Masayoshi Mori, Kazuhisa Matsunaga, Jiro Takata, Yoshiharu Karub. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PloS one. vol 13. issue 12. 2019-05-21. PMID:30557385. |
rivastigmine (riv) is a potent and selective cholinesterase (acetylcholinesterase, ache and butyrylcholinesterase, buche) inhibitor developed for the treatment of alzheimer's disease (ad). |
2019-05-21 |
2023-08-13 |
Not clear |
| Thomas Gilber. [Acetylcholinesterase inhibitors in Alzheimer's disease: the debate is not yet settled!]. La Revue du praticien. vol 66. issue 7. 2019-05-17. PMID:30512285. |
[acetylcholinesterase inhibitors in alzheimer's disease: the debate is not yet settled! |
2019-05-17 |
2023-08-13 |
Not clear |
| H Saleh, L Sadegh. Investigation of THDOC effects on pathophysiological signs of Alzheimer's disease as an endogenous neurosteroid: inhibition of acetylcholinesterase and plaque deposition. Bratislavske lekarske listy. vol 120. issue 2. 2019-05-15. PMID:30793620. |
investigation of thdoc effects on pathophysiological signs of alzheimer's disease as an endogenous neurosteroid: inhibition of acetylcholinesterase and plaque deposition. |
2019-05-15 |
2023-08-13 |
rat |
| H Saleh, L Sadegh. Investigation of THDOC effects on pathophysiological signs of Alzheimer's disease as an endogenous neurosteroid: inhibition of acetylcholinesterase and plaque deposition. Bratislavske lekarske listy. vol 120. issue 2. 2019-05-15. PMID:30793620. |
alzheimer's disease (ad) is an advanced neurodegenerative disorder greatly accompanied by acetylcholinesterase (ache) activation and amyloid plaque deposition. |
2019-05-15 |
2023-08-13 |
rat |
| Lucrezia Hausner, Lutz Frölic. [Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook]. Deutsche medizinische Wochenschrift (1946). vol 144. issue 3. 2019-05-02. PMID:30703832. |
antidementia therapy: the clinical use of acetylcholinesterase inhibitors (ache-i) for the symptomatic treatment of mild to moderate alzheimer's dementia is recognized worldwide, despite its modest effectiveness. |
2019-05-02 |
2023-08-13 |
Not clear |
| Mridula Saxena, Ragini Dube. Target Enzyme in Alzheimer's Disease: Acetylcholinesterase Inhibitors. Current topics in medicinal chemistry. vol 19. issue 4. 2019-04-24. PMID:30706815. |
target enzyme in alzheimer's disease: acetylcholinesterase inhibitors. |
2019-04-24 |
2023-08-13 |
Not clear |
| b' Jan Kor\\xc3\\xa1be\\xc4\\x8dn\\xc3\\xb. Melatonin as a structural template in the development of novel drugs for neurodegenerative disorders. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti. vol 67. issue 2. 2019-04-18. PMID:30189733.' |
key words: acetylcholinesterase • alzheimer's disease • antioxidant • butyrylcholinesterase • melatonin • neurodegenerative disorders. |
2019-04-18 |
2023-08-13 |
Not clear |
| Miroslav Pohank. [Cholinesterase activity assays and their use in the diagnosis of various pathological states including poisoning by neurotoxic agents]. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti. vol 66. issue 4. 2019-04-16. PMID:29351376. |
in the field of assays, spectrophotometric, colorimetric and electrochemical tests are discussed.key words: acetylcholinesterase butyrylcholinesterase poisoning liver function test pesticide nerve agent alzheimer disease pathological state. |
2019-04-16 |
2023-08-13 |
Not clear |
| Lixue Fan, Jiapeng Wang, Fanrong Meng, Yuan Luo, Xin Sui, Baoquan Zhao, Wanhua Li, Dongqin Quan, Jun Yang, Yongan Wan. Delivering the Acetylcholine Neurotransmitter by Nanodrugs as an Effective Treatment for Alzheimer's Disease. Journal of biomedical nanotechnology. vol 14. issue 12. 2019-04-16. PMID:30305214. |
the current clinical symptomatic therapy for alzheimer's disease involves increasing acetylcholine levels in the brain by inhibiting acetylcholinesterase. |
2019-04-16 |
2023-08-13 |
mouse |
| Hongye Pan, Jinghui Zhang, Yangyang Wang, Keke Cui, Yueting Cao, Longhu Wang, Yongjiang W. Linarin improves the dyskinesia recovery in Alzheimer's disease zebrafish by inhibiting the acetylcholinesterase activity. Life sciences. vol 222. 2019-03-28. PMID:30802512. |
linarin improves the dyskinesia recovery in alzheimer's disease zebrafish by inhibiting the acetylcholinesterase activity. |
2019-03-28 |
2023-08-13 |
zebrafish |
| Razan El Melik, Amanda Dubil, Melanie W Poun. Duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease as reported in the literature. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. vol 29. issue 6. 2019-03-27. PMID:25202893. |
duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate alzheimer's disease as reported in the literature. |
2019-03-27 |
2023-08-13 |
Not clear |